References
- 1. Hübel K, de la Rubbia J, Azar N, et al. Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective. Eur J Haematol. 2015;94:12-22.
- 2. Benekou K, Montoto S. Role of stem cell transplant in lymphoma in the era of new drugs. Curr Opin Oncol. 2017;29:455-459.10.1097/CCO.0000000000000403
- 3. Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18:1076-1088.10.1016/S1470-2045(17)30444-8
- 4. Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants. Bone Marrow Transplant. 2016;51:786-792.
- 5. Scheich S, Reinheimer C, Brandt C, et al: Clinical Impact of Colonization with Multidrug-Resistant Organisms on Outcome after Autologous Stem Cell Transplantation: A Retrospective Single-Center Study. Biol Blood Marrow Transplant. 2017;23:1455-1462.
- 6. Calmels B, Lemarie C, Esterni B, et al. Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product. Transfusion. 2007;47:1268-1275.10.1111/j.1537-2995.2007.01267.x
- 7. Jones JA, Qazilbash MH, Shih YC, et al. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. Cancer. 2008;112:1096-1105.
- 8. Otrock ZK, Sempek DS, Carey S, et al. Adverse events of cryopreserved hematopoietic stem cell infusions in adults: a single-center observational study. Transfusion. 2017;57:1522-1526.